{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T13:24:42Z","timestamp":1699536282118},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.56.8134","type":"journal-article","created":{"date-parts":[[2017,7,14]],"date-time":"2017-07-14T18:13:53Z","timestamp":1500056033000},"page":"1915-1918","source":"Crossref","is-referenced-by-count":7,"title":["Paraneoplastic Anti-3-hydroxy-3-methylglutary-coenzyme A Reductase Antibody-positive Immune-mediated Necrotizing Myopathy in a Patient with Uterine Cancer"],"prefix":"10.2169","volume":"56","author":[{"given":"Atsushi","family":"Mizuma","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Kouchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuka","family":"Netsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Yutani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruriko","family":"Kitao","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hakone Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Keio University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wakayama Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichiro","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunya","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokai University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC International Workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 14: 337-345, 2004."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Mammen AL, Chung T, Christopher-Stine L, et al. Auto-antibodies against 3-hydroxy-3-methylglutarylcoenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63: 713-721, 2011.","DOI":"10.1002\/art.30156"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 64: 269-272, 2012.","DOI":"10.1002\/acr.20662"},{"key":"4","unstructured":"4. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93: 150-157, 2014."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64: 4087-4093, 2012.","DOI":"10.1002\/art.34673"},{"key":"6","unstructured":"6. Alshehri A, Choksi R, Bucelli R, Restronk A. Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2: e124, 2015."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HNGCR necrotising myopathy. J Neurol Neurosurg Psychiatry 87: 1038-1044, 2016.","DOI":"10.1136\/jnnp-2016-313166"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Luo YB, Mastaglia FL. Dermatomyusitis, polymyositis and immune-mediated necroticsing myopathies. Biochim Biophys Acta 1852: 622-632, 2015.","DOI":"10.1016\/j.bbadis.2014.05.034"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord 17: 194-200, 2007.","DOI":"10.1016\/j.nmd.2006.10.007"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Shankaran V, Ikeda H, Bruce AT, et al. IFN\u03b3 and lympho-cytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111, 2001.","DOI":"10.1038\/35074122"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Nagaraju K, Raben N, Merritt G, et al. A variety of cytokines and immunologically relevant surface molecules are expressed by normal human skeletal muscle cells under proinflammatory stimuli. Clin Exp Immunol 113: 407-414, 1998.","DOI":"10.1046\/j.1365-2249.1998.00664.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Gustbee E, Tryggvadottir H, Markkula A, et al. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol 15: 8, 2015.","DOI":"10.1186\/s12907-015-0008-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Stine JE, Guo H, Sheng X, et al. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer. Oncotarget 7: 946-960, 2016.","DOI":"10.18632\/oncotarget.5834"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/14\/56_56.8134\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T04:58:10Z","timestamp":1569819490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/14\/56_56.8134\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":13,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.56.8134","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}